Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and Nab-paclitaxel in Advanced Gastric/GEJ Adenocarcinoma
NCT04140318Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Nov 2019
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Overall Response Rate up to 2 years. Status: unknown.
02
Drugs
sintilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04140318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04140318.